中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2015年
9期
1394-1397
,共4页
鼻咽肿瘤%顺铂%多西他赛%放射疗法
鼻嚥腫瘤%順鉑%多西他賽%放射療法
비인종류%순박%다서타새%방사요법
Nasopharyngeal neoplasms%Cisplatinum%Paclitaxe%Radiation therapy
目的 探讨多西他赛/顺铂联合放疗在局部晚期鼻咽癌治疗中的疗效及不良反应.方法 选取首次治疗的87例局部晚期鼻咽癌患者,随机分为多西他赛组(A组,n=43)与顺铂组(B组,n=44).化疗方法:A组每周用药1次,每次按30 mg/m2剂量用药,共用6次;B组每3周用药1次,每次按总剂量80～100 mg/m2分3d静脉滴注,共用2次.放疗方法:所有患者均使用头颈肩膜固定,采用调强放射治疗,处方剂量为PGTV、PGTVnd 6 996 cGy/33次,PTV1 6 006 cGy/33次,PTV2 5 096 cGy/28次.结果 放疗结束1个月后A、B两组鼻咽部及颈部病灶治疗的有效率分别为88.4％和86.4％(x2=0.079,P=0.778)、88.4％和88.6％(x2=0.000,P=1.000),差异无统计学意义;但B组口腔黏膜反应(x2=4.295,P=0.038)及胃肠道反应(x2=4.482,P=0.028)发生率明显高于A组.结论 晚期鼻咽癌根治性放疗联合多西他赛的治疗疗效与联合顺铂相似,且毒副反应较低,患者耐受性可,近期疗效满意.
目的 探討多西他賽/順鉑聯閤放療在跼部晚期鼻嚥癌治療中的療效及不良反應.方法 選取首次治療的87例跼部晚期鼻嚥癌患者,隨機分為多西他賽組(A組,n=43)與順鉑組(B組,n=44).化療方法:A組每週用藥1次,每次按30 mg/m2劑量用藥,共用6次;B組每3週用藥1次,每次按總劑量80～100 mg/m2分3d靜脈滴註,共用2次.放療方法:所有患者均使用頭頸肩膜固定,採用調彊放射治療,處方劑量為PGTV、PGTVnd 6 996 cGy/33次,PTV1 6 006 cGy/33次,PTV2 5 096 cGy/28次.結果 放療結束1箇月後A、B兩組鼻嚥部及頸部病竈治療的有效率分彆為88.4％和86.4％(x2=0.079,P=0.778)、88.4％和88.6％(x2=0.000,P=1.000),差異無統計學意義;但B組口腔黏膜反應(x2=4.295,P=0.038)及胃腸道反應(x2=4.482,P=0.028)髮生率明顯高于A組.結論 晚期鼻嚥癌根治性放療聯閤多西他賽的治療療效與聯閤順鉑相似,且毒副反應較低,患者耐受性可,近期療效滿意.
목적 탐토다서타새/순박연합방료재국부만기비인암치료중적료효급불량반응.방법 선취수차치료적87례국부만기비인암환자,수궤분위다서타새조(A조,n=43)여순박조(B조,n=44).화료방법:A조매주용약1차,매차안30 mg/m2제량용약,공용6차;B조매3주용약1차,매차안총제량80～100 mg/m2분3d정맥적주,공용2차.방료방법:소유환자균사용두경견막고정,채용조강방사치료,처방제량위PGTV、PGTVnd 6 996 cGy/33차,PTV1 6 006 cGy/33차,PTV2 5 096 cGy/28차.결과 방료결속1개월후A、B량조비인부급경부병조치료적유효솔분별위88.4％화86.4％(x2=0.079,P=0.778)、88.4％화88.6％(x2=0.000,P=1.000),차이무통계학의의;단B조구강점막반응(x2=4.295,P=0.038)급위장도반응(x2=4.482,P=0.028)발생솔명현고우A조.결론 만기비인암근치성방료연합다서타새적치료료효여연합순박상사,차독부반응교저,환자내수성가,근기료효만의.
Objective To observe the acute side effects and recent therapeutical effect of cisplatinum/paclitaxe concurrent radiotherapy for patients with advanced nasopharyngeal carcinoma.Methods 87 patients with advanced nasopharygeal carcinoma were enrolled.According to the treatment,87 patients were divided into paclitaxe group (groupA,n =43) and cisplatinum group (group B,n =44).The two groups were treated with 6MV-X ray for radiotherapy.The prescription dose of radiation therapy was PGTV,PGTVnd 6 996 cGy/33F,PTV1 6 006 cGy/33F,PTV2 5 096 cGy/28F.The two groups began concurrent chemotherapy in radiotherapy,specific method:group A paclitaxe 30mg/m2,1 time a week,until the end of radiotherapy,group B cisplatinum 80 ～100 mg/m2,every 21 days.Results The recent therapeutical effect of nasopharyngeal lesions and lymph nodes of neck for group A and group B were 88.4％ and 86.4％ (x2 =0.079,P =0.778),88.4％ and 88.6％ (x2 =0.000,P =1.000),respectively.But the occurrence rate of group B ' oral mucosa reaction (x2 =4.295,P =0.038) and gastrointestinal reaction (x2 =4.482,P =0.028) were higher than that of group A.Conclusion Treated with cisplatin in advanced nasopharyngeal carcinoma after radical radiotherapy combined with docetaxel is similar,and the side effect is low,the tolerance of patients is good,curative effect is satisfied.
